Loading…

Haemonetics CorporationHAECompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Maker of blood and plasma collection, processing devices and software used by blood centers, hospitals and plasma companies.

Momentum leader 96
Mkt cap
$5.59B
US dollars, full cap
Free float
98%
of shares outstanding
$/day
$82.3M
20-day average traded
Fwd P/E
20.7×
forward earnings
ROIC−WACC
+3.7 pp
WACC 7.8%
Hurdle
+2 pp
Req g minus delivered
Next earnings
85 days
11 Feb 2027
Close · USD$122.86
1D+1.6%
1W+1.9%
1M+3.9%
3M+13.5%
6M+106.3%
YTD+53.3%
1Y+65.3%
ATR %3.4%
Beta0.28
52w lowhigh6.9% off high

What Haemonetics does

Maker of blood and plasma collection, processing devices and software used by blood centers, hospitals and plasma companies.

Places collection machines in plasma and blood centres, then earns repeatedly on the single-use sets each collection needs, a razor-and-blade model. A few large plasma-product makers' collection networks account for a large share of plasma sales. The hospital side sells blood-clot testing and surgical products.

Products and services

  • Plasma collection devices
  • Blood management/surgical hemostasis devices
  • Vascular closure devices
  • Software (blood-bank management)

Customers

  • Blood/plasma collection centers
  • Hospitals
  • Plasma-product manufacturers

Where it sits in the supply chain

  • Medical devices
  • Blood/plasma management
  • Blood collection, processing & software

What could go right

  • Global plasma demand growth
  • Vascular/surgical hemostasis expansion

What could go wrong

  • Plasma-center capex cyclicality
  • Customer concentration in plasma industry

Moat: narrow (switching costs, installed base, regulatory licence). Installed base of collection devices and disposables creates recurring, sticky consumable revenue.

Headquarters: Boston, Massachusetts · Founded: 1971 · Employees: 3,009

Named competitors

Haemonetics at a glance

Size Haemonetics (HAE) is a United States Health Care company (Medical Specialties) with a market value of $5.59B, the 1099th largest of 3,085 United States companies the cockpit tracks. Shares closed at $122.86 on 18 Nov 2026.

Performance Over six months the shares gained 106.3%, against +25.7% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 21 in its peer set.

Growth Revenue grew 4.1% over the last twelve months (peer median +6.8%); the operating margin is 18.5% (peer median 15.7%).

Valuation It trades at 20.7× forward earnings against a peer median of 20.5× (10th most expensive of 20).

Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 3.7 points above its cost of capital (7.8% WACC).

Backlog Backlog (remaining performance obligations) was $30.1M at 26 Sep 2026, down 15% on a year earlier — 0.0 years of trailing revenue. Backlog detail →

Credit Haemonetics has 1 bond outstanding ($700M).

Short interest Short interest is 7.9% of the free float (30 Oct 2026).

Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026HAE 198Peer median 127
Six months, rebased to 100: Haemonetics against the median of its 20 peers (local-currency closes).

Haemonetics financials

Reported figures in USD; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$1.38B$1.33B$1.36B$1.31B$1.17B
Revenue growth—-2%+4%+12%—
Gross profit$783M$743M$715M$677M$590M
EBITDA$366M$356M$338M$305M$261M
Net income$104M$97.3M$168M$118M$115M
Free cash flow$298M$260M$142M$115M$162M
Capital expenditure$46.7M$32.8M$39.3M$66.3M$110M
Total debt$1.12B$1.27B$1.28B$874M$773M

Quarterly statements and history in the cockpit →

Haemonetics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+25%+50%+75%+100%-20%0%+20%LIVN688617MMSI300677DIAMMEDTFXLNTHCOHSHCCTECGRALYPSNICUI7747BLCOGETI-BSTVN002223300832HAE6-month return →1-month return →
Up and to the right = strong over both horizons. Haemonetics is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%20×30×40×LIVN688617MMSI300677DIAMMEDTFXLNTHCOHSHCCTECYPSNICUI7747BLCOSTVN300832HAERevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Haemonetics is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%LIVN688617MMSI300677DIATFXLNTHCOHCTECICUI7747BLCOGETI-B300832HAEGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Haemonetics is the large dot.

Haemonetics competitors and peer comparison

Head to head with its named competitors (HAE vs 4543.T vs GRF.MC vs CSL.AX)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Haemonetics HAE$5.59B+106%+4%19%20.7×10.9%
Terumo 4543.T$24.0B+32%+15%17%27.8×8.8%
Grifols GRF.MC$7.48B+19%+1%16%13.1×7.1%
CSL CSL.AX$63.7B+102%-2%26%21.5×6.8%
Teleflex TFX$6.58B+23%-29%12%16.7×16.5%
Baxter International BAX$13.5B+39%+5%6%12.7×13.4%
Cerus CERS$392M-28%+14%-12%n/an/a

How Haemonetics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Haemonetics against its 20 peers (data as of 18 Nov 2026)
MeasureHAEPeer medianRank in peer set
1-month return+3.9%+10.6%8th lowest of 21
6-month return+106.3%+25.7%highest of 21
Distance from 52-week high-6.9%-7.8%10th highest of 21
Revenue growth (TTM)+4.1%+6.8%10th lowest of 21
Operating margin18.5%15.7%9th highest of 21
Forward P/E20.7×20.5×10th most expensive of 20
Growth the price implies (Req g, 7 yrs)10.9%12.6%8th least demanding of 18
Growth delivered (Del g)+8.9%+9.3%9th lowest of 18
Hurdle (Req g minus delivered)+2.0 pp+2.0 pp9th most demanding of 18
ROIC minus cost of capital+3.7 pp+2.5 pp8th highest of 21
EV / EBITDA17.7×14.2×5th most expensive of 16
Net debt / EBITDA2.4×1.1×6th most indebted of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Haemonetics HAEUnited States$5.59B+106%+4%19%20.7×10.9%+8.9%
LivaNova LIVNUnited States$5.21B+28%+12%15%20.9×14.2%+8.2%
APT Medical 688617.SSChina$6.06B+23%+28%37%38.6×9.0%+40.1%
Merit Medical Systems MMSIUnited States$5.15B+33%+9%14%19.1×12.6%+9.5%
Intco Medical Technology 300677.SZChina$4.82B-2%+33%20%18.5×-3.5%-6.4%
DiaSorin DIA.MIItaly$4.81B+24%-3%24%20.5×4.1%+6.3%
MiniMed MMEDUnited States$4.78B+46%+14%14%26.3×n/an/a
Teleflex TFXUnited States$6.58B+23%-29%12%16.7×16.5%-4.7%
Lantheus LNTHUnited States$6.67B+6%+2%19%15.5×0.4%+35.3%
Cochlear COH.AXAustralia$6.72B+58%-1%13%29.1×23.9%+9.3%
Sotera Health SHCUnited States$4.65B+5%+7%37%15.7×14.4%+7.3%
ConvaTec CTEC.LUnited Kingdom$6.78B+37%+2%16%17.7×17.2%+4.6%
GRAIL GRALUnited States$4.59B+67%+17%-332%n/an/an/a
Ypsomed YPSN.SWSwitzerland$6.83B+27%-13%30%31.7×n/an/a
ICU Medical ICUIUnited States$4.46B+38%-6%8%19.4×18.9%+11.9%
Asahi Intecc 7747.TJapan$7.09B+24%+23%32%29.7×15.1%+18.8%
Bausch + Lomb BLCO.TOCanada$7.41B+35%+11%9%18.3×12.0%+10.0%
Getinge GETI-B.STSweden$7.45B+40%-4%14%21.1×5.0%+3.2%
Stevanato STVNUnited States$4.19B-13%+12%18%22.5×13.1%+12.1%
Jiangsu Yuyue Medical Equipment & Supply 002223.SZChina$4.18B-3%-1%13%20.0×4.9%+3.4%
Shenzhen New Industries Biomedical Engineering 300832.SZChina$7.50B+21%+7%43%26.9×2.9%+15.7%

Haemonetics bonds and credit

Haemonetics has 1 bond outstanding with $700M face value.

Every bond, yield and spread in the cockpit →

Haemonetics backlog

Haemonetics reported $30.1M of remaining performance obligations at 26 Sep 2026, down 15% from a year earlier and down 3% from the previous quarter. That is 0.0 years of trailing revenue already under contract. Book-to-bill last quarter: 1.00.

Questions

Who are Haemonetics's main competitors?
Named competitors: Terumo Corp (4543.T), Fresenius Kabi (private or unlisted), Grifols (GRF.MC), CSL Limited (CSL.AX), Teleflex (TFX), Baxter International (BAX). The cockpit's measured peer set (industry) also includes LivaNova (LIVN), APT Medical (688617.SS), Merit Medical Systems (MMSI), Intco Medical Technology (300677.SZ), DiaSorin (DIA.MI), MiniMed (MMED).
Is Haemonetics expensive compared with its peers?
On forward p/e it trades at 20.7× against a peer median of 20.5×, 10th most expensive of 20 in its peer set. For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Haemonetics stock performed?
Over six months to 18 Nov 2026 the shares returned +106.3% against +25.7% for the median peer; over one year +65.3%.
What is Haemonetics's backlog?
Haemonetics's remaining performance obligations (contracted revenue not yet recognised) were $30.1M at 26 Sep 2026, -15% on a year earlier.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.